{"protocolSection":{"identificationModule":{"nctId":"NCT02848651","orgStudyIdInfo":{"id":"ML39237"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer","officialTitle":"A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics","acronym":"B-F1RST"},"statusModule":{"statusVerifiedDate":"2020-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-05-14","type":"ACTUAL"},"completionDateStruct":{"date":"2019-05-14","type":"ACTUAL"},"studyFirstSubmitDate":"2016-07-26","studyFirstSubmitQcDate":"2016-07-26","studyFirstPostDateStruct":{"date":"2016-07-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-04-15","resultsFirstSubmitQcDate":"2020-04-15","resultsFirstPostDateStruct":{"date":"2020-04-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-04-15","lastUpdatePostDateStruct":{"date":"2020-04-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This was a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab as a first-line therapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). In addition, the primary biomarker objective was to measure blood tumor mutational burden (bTMB) and evaluate whether it can predict for improved clinical outcome with atezolizumab."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":153,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atezolizumab","type":"EXPERIMENTAL","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).","interventionNames":["Drug: Atezolizumab"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab","description":"Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).","armGroupLabels":["Atezolizumab"],"otherNames":["MPDL3280A; RO5541267; Tecentriq"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator","description":"Investigator-assessed objective response rate was defined as the proportion of participants who had a confirmed best overall response of either PR or CR per RECIST v1.1.","timeFrame":"Baseline up to 32 months"},{"measure":"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups","description":"Investigator-assessed PFS by RECIST v1.1 was defined as the time from the first dose of study drug to the time of PD or death from any cause during the study, whichever occurred first.","timeFrame":"Baseline up to 32 months"}],"secondaryOutcomes":[{"measure":"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator","description":"Investigator-assessed PFS by RECIST v1.1 was defined as the time from the first dose of study drug to the time of PD or death from any cause during the study, whichever occurred first.","timeFrame":"Baseline up to 32 months"},{"measure":"Duration of Response (DOR) Per RECIST v1.1 as Determined by Investigator","description":"Investigator-assessed DOR by RECIST v1.1 was defined as the time from initial occurrence of documented CR or PR until documented disease progression as determined by the investigator, or death, whichever occurred first.","timeFrame":"Baseline up to 32 months"},{"measure":"Disease Control Rate (DCR) Per RECIST v1.1 as Determined by Investigator","description":"Confirmed disease control rate (cDCR) was defined as the rate of patients with CR or PR as the best response, or SD maintained for 24 weeks, per RECIST v1.1.","timeFrame":"Baseline up to 32 months"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from the first dose of study drug to the time of death from any cause during the study.","timeFrame":"From baseline until death (up to 32 months)"},{"measure":"Percentage of Participants With Adverse Events","description":"Adverse events were defined as any untoward medical occurrence in a subject administered atezolizumab, regardless of causal attribution.","timeFrame":"Baseline up to 32 months"},{"measure":"Percentage of Participants Who Are Alive and Progression-Free (Per RECIST v1.1) at 6, 9, 12, and 18 Months by Various bTMB Quantiles","description":"A summary of the number of patients at risk and survival rate for the time points of 6, 9, 12, and 18 months.","timeFrame":"Months 6, 9, 12, and 18"},{"measure":"OS by Various bTMB Cutoff Points 16 and 20","description":"OS was defined as the time from the first dose of study drug to the time of death from any cause during the study.","timeFrame":"From baseline until death (up to 32 months)"},{"measure":"Percentage of Participants With Objective Response (Per RECIST v1.1) by Various bTMB Quantiles","description":"Objective response rate was defined as the proportion of participants who had a confirmed best overall response of either PR or CR per RECIST v1.1.","timeFrame":"Baseline up to 32 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically or cytologically confirmed Stage IIIB-IVB NSCLC\n* For participants who have received prior neo-adjuvant/adjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease: a treatment-free interval of at least 6 months prior to enrollment\n* Participants with any programmed death-ligand 1 (PD-L1) test result by immunohistochemistry (IHC) are eligible for the study\n* Participants without a PD-L1 test result are eligible for the study\n* Measurable disease per RECIST v1.1\n* Adequate hematologic and end-organ function\n* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods among women of childbearing potential\n\nExclusion Criteria:\n\n* Prior treatment with immunotherapy for any stage NSCLC, including early-stage (neoadjuvant or adjuvant) disease\n* Participants with epidermal growth factor receptor (EGFR) sensitizing mutations and anaplastic lymphoma kinase (ALK) rearrangements\n* Active central nervous system (CNS) metastases requiring treatment\n* Spinal cord compression not definitively treated or not clinically stable\n* Leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Malignancies other than NSCLC within 5 years prior to enrollment, except for those curatively treated with negligible risk of metastasis or death\n* Pregnant or lactating women\n* History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease\n* Positive human immunodeficiency virus (HIV) or hepatitis B or C\n* Active tuberculosis\n* Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollment\n* Prior treatment with or hypersensitivity to study drug or related compounds\n* Prior allogeneic bone marrow or solid organ transplant\n* Administration of a live, attenuated vaccine within 4 weeks prior to enrollment\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to enrollment\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Veterans Affairs Central California Health Care System","city":"Fresno","state":"California","zip":"93703","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Memorial Regional Hospital","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Florida Hospital","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"St. Alexius Medical Center","city":"Hoffman Estates","state":"Illinois","zip":"60169","country":"United States","geoPoint":{"lat":42.04281,"lon":-88.0798}},{"facility":"Quincy Medical Group; Canc Ctr at Blessing Hosp","city":"Quincy","state":"Illinois","zip":"62301","country":"United States","geoPoint":{"lat":39.9356,"lon":-91.40987}},{"facility":"Franciscan St. Francis Health; Research Services","city":"Indianapolis","state":"Indiana","zip":"46237","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Cancer Center of Kansas","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Michigan Cancer Rsch Cons","city":"Ypsilanti","state":"Michigan","zip":"48197","country":"United States","geoPoint":{"lat":42.24115,"lon":-83.61299}},{"facility":"Virginia Piper Cancer Inst","city":"Minneapolis","state":"Minnesota","zip":"55407","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"San Juan Oncology Associates","city":"Farmington","state":"New Mexico","zip":"87401","country":"United States","geoPoint":{"lat":36.72806,"lon":-108.21869}},{"facility":"Stony Brook University Medical Center","city":"Stony Brook","state":"New York","zip":"11794","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"Eastchester Center for Cancer Care","city":"The Bronx","state":"New York","zip":"10469","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"The Cleveland Clinic Foundation","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Cancer Treatment Centers of America - Eastern Regional Medical Center","city":"Philadelphia","state":"Pennsylvania","zip":"19124","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Avera Research Institute","city":"Sioux Falls","state":"South Dakota","zip":"57105","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"Univ of Texas SW Medical Ctr","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Inova Health Care Services","city":"Falls Church","state":"Virginia","zip":"22042","country":"United States","geoPoint":{"lat":38.88233,"lon":-77.17109}},{"facility":"Western WA Oncology Inc PS","city":"Lacey","state":"Washington","zip":"98503","country":"United States","geoPoint":{"lat":47.03426,"lon":-122.82319}},{"facility":"University of Wisconsin","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}}]},"referencesModule":{"references":[{"pmid":"35422531","type":"DERIVED","citation":"Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"153"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"152"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"106"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"85"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Non-Compliance","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Symptomatic Deterioration","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"152"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.7","spread":"9.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"69"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"83"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"147"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"135"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator","description":"Investigator-assessed objective response rate was defined as the proportion of participants who had a confirmed best overall response of either PR or CR per RECIST v1.1.","populationDescription":"Efficacy and Safety analysis Population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"11.62","upperLimit":"23.86"}]}]}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups","description":"Investigator-assessed PFS by RECIST v1.1 was defined as the time from the first dose of study drug to the time of PD or death from any cause during the study, whichever occurred first.","populationDescription":"Biomarker analysis population included all participants who received at least one dose of study drug and whose tumor samples had a maximum somatic allele frequency (MSAF) \\>= 1%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"bTMB Low (<16)","description":"Blood tumor mutational burdern (bTMB) Low (\\<16)"},{"id":"OG001","title":"bTMB High (>=16)","description":"Blood tumor mutational burden (bTMB) High (\\>=16)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","lowerLimit":"2.63","upperLimit":"4.30"},{"groupId":"OG001","value":"4.98","lowerLimit":"1.58","upperLimit":"10.81"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3502","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.80","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"1.18"}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator","description":"Investigator-assessed PFS by RECIST v1.1 was defined as the time from the first dose of study drug to the time of PD or death from any cause during the study, whichever occurred first.","populationDescription":"Efficacy Evaluable Population included all participants who received at least one dose of atezolizumab.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","lowerLimit":"2.76","upperLimit":"4.90"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) Per RECIST v1.1 as Determined by Investigator","description":"Investigator-assessed DOR by RECIST v1.1 was defined as the time from initial occurrence of documented CR or PR until documented disease progression as determined by the investigator, or death, whichever occurred first.","populationDescription":"Duration of response included a subset of participants who achieved an objective response in the efficacy evaluable population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.33","lowerLimit":"10.15","upperLimit":"NA","comment":"Upper limit is not available because at the time of data cutoff, the upper limit of 95% CI is not estimable."}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) Per RECIST v1.1 as Determined by Investigator","description":"Confirmed disease control rate (cDCR) was defined as the rate of patients with CR or PR as the best response, or SD maintained for 24 weeks, per RECIST v1.1.","populationDescription":"Efficacy Evaluable Population included all participants who received at least one dose of atezolizumab.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"25.50","upperLimit":"40.74"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from the first dose of study drug to the time of death from any cause during the study.","populationDescription":"Efficacy Evaluable Population included all participants who received at least one dose of atezolizumab.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From baseline until death (up to 32 months)","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.82","lowerLimit":"12.68","upperLimit":"21.29"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"Adverse events were defined as any untoward medical occurrence in a subject administered atezolizumab, regardless of causal attribution.","populationDescription":"Safety analyses population included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive and Progression-Free (Per RECIST v1.1) at 6, 9, 12, and 18 Months by Various bTMB Quantiles","description":"A summary of the number of patients at risk and survival rate for the time points of 6, 9, 12, and 18 months.","populationDescription":"Biomarker analysis population included all participants who received at least one dose of study drug and whose tumor samples had a maximum somatic allele frequency (MSAF) \\>=1%.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Months 6, 9, 12, and 18","groups":[{"id":"OG000","title":"bTMB <10","description":"Blood tumor mutational burden (bTMB) \\<10."},{"id":"OG001","title":"bTMB >=10","description":"Blood tumor mutational burden (bTMb) \\>=10."},{"id":"OG002","title":"bTMB <16","description":"Blood tumor mutational burden (bTMB) \\<16."},{"id":"OG003","title":"bTMB >=16","description":"Blood tumor mutational burden (bTMB) \\>=16."},{"id":"OG004","title":"bTMB <20","description":"Blood tumor mutational burden (bTMB) \\<20."},{"id":"OG005","title":"bTMB >=20","description":"Blood tumor mutational burden (bTMB) \\>=20."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"6 Months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.67","lowerLimit":"23.91","upperLimit":"47.43"},{"groupId":"OG001","value":"34.69","lowerLimit":"21.37","upperLimit":"48.02"},{"groupId":"OG002","value":"32.85","lowerLimit":"22.85","upperLimit":"42.86"},{"groupId":"OG003","value":"42.86","lowerLimit":"24.53","upperLimit":"61.19"},{"groupId":"OG004","value":"31.91","lowerLimit":"22.47","upperLimit":"41.34"},{"groupId":"OG005","value":"52.63","lowerLimit":"30.18","upperLimit":"75.08"}]}]},{"title":"9 Months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.19","lowerLimit":"12.51","upperLimit":"33.86"},{"groupId":"OG001","value":"22.45","lowerLimit":"10.77","upperLimit":"34.13"},{"groupId":"OG002","value":"16.90","lowerLimit":"8.60","upperLimit":"25.19"},{"groupId":"OG003","value":"39.29","lowerLimit":"21.20","upperLimit":"57.38"},{"groupId":"OG004","value":"17.58","lowerLimit":"9.61","upperLimit":"25.55"},{"groupId":"OG005","value":"47.37","lowerLimit":"24.92","upperLimit":"69.82"}]}]},{"title":"12 Months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.86","lowerLimit":"6.99","upperLimit":"26.74"},{"groupId":"OG001","value":"14.29","lowerLimit":"4.49","upperLimit":"24.08"},{"groupId":"OG002","value":"12.29","lowerLimit":"4.79","upperLimit":"19.78"},{"groupId":"OG003","value":"25.00","lowerLimit":"8.96","upperLimit":"41.04"},{"groupId":"OG004","value":"12.24","lowerLimit":"5.17","upperLimit":"19.31"},{"groupId":"OG005","value":"31.58","lowerLimit":"10.68","upperLimit":"52.48"}]}]},{"title":"18 Months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.45","lowerLimit":"4.93","upperLimit":"23.98"},{"groupId":"OG001","value":"8.16","lowerLimit":"0.50","upperLimit":"15.83"},{"groupId":"OG002","value":"10.53","lowerLimit":"3.36","upperLimit":"17.70"},{"groupId":"OG003","value":"14.29","lowerLimit":"1.32","upperLimit":"27.25"},{"groupId":"OG004","value":"9.33","lowerLimit":"2.88","upperLimit":"15.78"},{"groupId":"OG005","value":"21.05","lowerLimit":"2.72","upperLimit":"39.38"}]}]}]},{"type":"SECONDARY","title":"OS by Various bTMB Cutoff Points 16 and 20","description":"OS was defined as the time from the first dose of study drug to the time of death from any cause during the study.","populationDescription":"Biomarker analysis population included all participants who received at least one dose of study drug and whose tumor samples had a maximum somatic allele frequency (MSAF) \\>= 1%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From baseline until death (up to 32 months)","groups":[{"id":"OG000","title":"bTMB <16","description":"Blood tumor mutational burden (bTMB) \\<16."},{"id":"OG001","title":"bTMB >=16","description":"Blood tumor mutational burden (bTMB) \\>=16."},{"id":"OG002","title":"bTMB <20","description":"Blood tumor mutational burden (bTMB) \\<20"},{"id":"OG003","title":"bTMB >=20","description":"Blood tumor mutational burden (bTMB) \\>=20."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.37","lowerLimit":"11.70","upperLimit":"18.00"},{"groupId":"OG001","value":"23.85","lowerLimit":"8.77","upperLimit":"NA","comment":"Upper limit is not available because at the time of data cutoff, the upper limit of 95% CI is not estimable."},{"groupId":"OG002","value":"13.14","lowerLimit":"10.48","upperLimit":"17.71"},{"groupId":"OG003","value":"23.85","lowerLimit":"15.70","upperLimit":"NA","comment":"Upper limit is not available because at the time of data cutoff, the upper limit of 95% CI is not estimable."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1783","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.66","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"1.10"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0358","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.44","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.23","ciUpperLimit":"0.85"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response (Per RECIST v1.1) by Various bTMB Quantiles","description":"Objective response rate was defined as the proportion of participants who had a confirmed best overall response of either PR or CR per RECIST v1.1.","populationDescription":"Biomarker analysis population included all participants who received at least one dose of study drug and whose tumor samples had a maximum somatic allele frequency (MSAF) \\>=1%.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline up to 32 months","groups":[{"id":"OG000","title":"bTMB <10","description":"Blood tumor mutational burden (bTMB) \\<10."},{"id":"OG001","title":"bTMB >=10","description":"Blood tumor mutational burden (bTMB) \\>=10."},{"id":"OG002","title":"bTMB <16","description":"Blood tumor mutational burdern (bTMB) \\<16."},{"id":"OG003","title":"bTMB >=16","description":"Blood tumor mutational burden (bTMB) \\>=16."},{"id":"OG004","title":"bTMF <20","description":"Blood tumor mutational burden (bTMB) \\<20."},{"id":"OG005","title":"bTMF >=20","description":"Blood tumor mutational burden (bTMB) \\>=20."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"91"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"2.86","upperLimit":"15.32"},{"groupId":"OG001","value":"20.4","lowerLimit":"10.51","upperLimit":"33.73"},{"groupId":"OG002","value":"5.5","lowerLimit":"2.19","upperLimit":"12.25"},{"groupId":"OG003","value":"35.7","lowerLimit":"19.25","upperLimit":"55.54"},{"groupId":"OG004","value":"6.0","lowerLimit":"2.64","upperLimit":"12.19"},{"groupId":"OG005","value":"47.4","lowerLimit":"25.17","upperLimit":"69.15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0326","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Differences in Rates","paramValue":"13.27","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.53","ciUpperLimit":"24.00"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Difference in Rates","paramValue":"30.22","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"14.82","ciUpperLimit":"45.62"},{"groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Differences in Rates","paramValue":"41.37","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"22.13","ciUpperLimit":"60.61"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline up to approximately 3 years (data cut off 26 July 2019).","eventGroups":[{"id":"EG000","title":"Atezolizumab","description":"Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).","deathsNumAffected":85,"deathsNumAtRisk":152,"seriousNumAffected":81,"seriousNumAtRisk":152,"otherNumAffected":146,"otherNumAtRisk":152}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Aortic valve stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":152}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Peptic ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":152}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":152}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Seroma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":152}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":152}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":152}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pulmonary artery occlusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":152}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":152}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":152}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":152}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":152}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":152}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":152}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":152}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":152}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":152}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":152}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":152}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":152}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":152}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":152}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":152}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":152}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":152}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":152}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":152}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":152}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":152}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":152}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":152}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":152}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":152}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":152}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":152}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":152}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":152}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":152}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-04-29","uploadDate":"2020-04-15T16:27","filename":"Prot_000.pdf","size":2083682},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-01-17","uploadDate":"2020-04-15T16:27","filename":"SAP_001.pdf","size":335525}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"}]}},"hasResults":true}